Analysts at Daol Securities (Thailand) maintain a "Buy" recommendation for MEDEZE Group Plc. (SET:...
Southeast Asia Stem Cell Leader Medeze Launches Partial Offer for 10% Stake in SGX-listed Cordlife Group
Offer price of S$0.25 per share is at an attractive premium of 61.3% over...
MEDEZE Expects 30% Growth in 1Q25 with Biotech Investment for New S-Curve
Phiphat Phisanuwongrak, Chief Financial Officer of Medize Group Public Company Limited (SET: MEDEZE), presented...
MEDEZE Plans to Develop Advance Medical Product with Government Supports
MEDEZE Group Public Company Limited (SET: MEDEZE) is poised to benefit from the Ministry...
MEDEZE Jumps 10% on Potential Sandbox to Benefit Stem Cell Segment
On Tuesday at 10:10 AM (Bangkok time), the share price of Medeze Group Public...
MEDEZE Establishes New Subsidiary to Engage in Hair Follicle Stem Cells Business
Medeze Group Public Company Limited (SET: MEDEZE) has informed the Stock Exchange of Thailand...